Heart Test Laboratories Inc (HSCS)

$3.24 -0.13 (-3.86%)
Market Cap 2.27M
Revenue (ttm) 20,000.00
Net Income (ttm) -6.61M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 11,938
Avg Vol 455,542
Day's Range N/A - N/A
Shares Out 656,000.00
Stochastic %K 24%
Beta 3.16
Analysts Strong Sell
Price Target $13.50

Company Profile

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG info...

Industry: Medical Devices
Sector: Healthcare
Phone: 682-237-7781
Address:
550 Reserve Street, Suite 360, Southlake, United States
DrTampa
DrTampa Jul. 31 at 5:08 AM
$HSCS glad to see the offering is filling! We are 1/3 of the way done on the capital raise to see us through FDA submission approval and into commercialization!
0 · Reply
Moneyybaggs
Moneyybaggs Jul. 31 at 12:19 AM
$HSCS First of all, HSCS is raising $15 million and each unit is being issued at $3.50 per share with a $5 strike warrant that expires in three years. I spoke with the firm running the books and the raise is going very well.
0 · Reply
JerrieGauze
JerrieGauze Jul. 30 at 10:46 PM
$HSCS of July 29, 2025, the Company has received a total of $4.3 million of gross proceeds, resulting in the issuance of 1,241,188 Units, as a result of several closings of the Offering. they offered 15 million units. they need total 25 mil in shareholder value by sept 15 i know of one not personally( unless lying) is sweating this one. gl
0 · Reply
JerrieGauze
JerrieGauze Jul. 30 at 3:50 PM
$HSCS Science has left the building tongue blade ,ambu bag, and start heart compressions..more orders to come
0 · Reply
upmarketguy
upmarketguy Jul. 28 at 5:17 PM
$HSCS Out of this IDK why I got in it. Such light volume. Glad I didn't have much of it.
1 · Reply
DrTampa
DrTampa Jul. 28 at 4:33 AM
$HSCS I'm thinking this week could be very interesting...it didn't drop on earnings, and in fact had a little rally. Someone else sees the potential us long time holders see!
0 · Reply
d_risk
d_risk Jul. 25 at 4:59 PM
$HSCS - Heart Test Laboratories, Inc. - 10K - Updated Risk Factors HSCS’s 2025 10-K reveals expanded clinical trial and FDA compliance risks, heightened IP litigation and patent uncertainties, new dependency on Mount Sinai licenses, increased regulatory scrutiny on off-label use and inducements, added public company compliance burdens, potential stock dilution from preferred shares, and FINRA trading restrictions. #ClinicalTrials #StockDilution #RegulatoryScrutiny #IPLitigation #FDACompliance 🟢 Added 🟠 Removed https://d-risk.ai/HSCS/10-K/2025-07-24
1 · Reply
DrTampa
DrTampa Jul. 25 at 6:47 AM
$HSCS btw with the cash burn from the last quarter that they won't report for quite some time, I estimate another $1.5 million so shareholder equity is at about $2.3 million currently. keep in mind these are just estimates based on past expenses, and it's certainly not financial advice. But I think with the open offering taking place, we should definitely hit 3.5 million in equity by the end of the next quarter. We may not even need the NASDAQ extension which could grant us another 6 months for compliance if needed.
0 · Reply
14745Barclay
14745Barclay Jul. 24 at 10:35 PM
$HSCS Simpson, Hilz and Watson keep on giving themselves raises and bonuses and all the while dragging their feet with FDA submission of Myovista waveECG device. More excuses now with the some stupid update from ECG society guideline. Us long time shareholders have been suffering so much and these incompetent managers are milking us dry.
2 · Reply
DrTampa
DrTampa Jul. 24 at 8:19 PM
$HSCS 10-K just dropped! Reading it now :P
0 · Reply
Latest News on HSCS
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

Jul 24, 2025, 4:15 PM EDT - 6 days ago

HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Jun 4, 2025, 9:00 AM EDT - 2 months ago

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value

Jun 3, 2025, 9:00 AM EDT - 2 months ago

Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

May 29, 2025, 9:00 AM EDT - 2 months ago

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

May 20, 2025, 9:00 AM EDT - 2 months ago

HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

May 8, 2025, 9:00 AM EDT - 2 months ago

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

May 7, 2025, 9:00 AM EDT - 3 months ago

HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

May 1, 2025, 9:00 AM EDT - 3 months ago

HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

Mar 13, 2025, 4:15 PM EDT - 4 months ago

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

Mar 10, 2025, 9:00 AM EDT - 5 months ago

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

Dec 16, 2024, 4:15 PM EST - 8 months ago

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Nov 13, 2024, 9:00 AM EST - 9 months ago

HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 14, 2024, 4:15 PM EDT - 10 months ago

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

Sep 12, 2024, 4:15 PM EDT - 11 months ago

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

Sep 12, 2024, 9:00 AM EDT - 11 months ago

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Jul 29, 2024, 4:05 PM EDT - 1 year ago

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

Jul 26, 2024, 9:00 AM EDT - 1 year ago

Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

Jul 25, 2024, 8:30 AM EDT - 1 year ago

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Jul 11, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

HeartSciences Regains Compliance with Nasdaq Listing Requirements

Jun 4, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Regains Compliance with Nasdaq Listing Requirements

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

May 20, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Apr 24, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

HeartSciences to Present at the LD Micro Invitational XIV Conference

Apr 2, 2024, 4:15 PM EDT - 1 year ago

HeartSciences to Present at the LD Micro Invitational XIV Conference

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Mar 26, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Mar 14, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Mar 12, 2024, 9:00 AM EDT - 1 year ago

HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

Mar 6, 2024, 9:00 AM EST - 1 year ago

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Feb 26, 2024, 9:00 AM EST - 1 year ago

HeartSciences Adds Key Advisor to its Scientific Advisory Board

HeartSciences Expands its Scientific Advisory Board

Feb 12, 2024, 9:00 AM EST - 1 year ago

HeartSciences Expands its Scientific Advisory Board

HeartSciences Appoints New Scientific Advisory Board Member

Feb 1, 2024, 9:00 AM EST - 1 year ago

HeartSciences Appoints New Scientific Advisory Board Member

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

Jan 18, 2024, 8:00 AM EST - 1 year ago

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

Jan 3, 2024, 4:15 PM EST - 1 year ago

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:15 PM EST - 1 year ago

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

Dec 5, 2023, 8:00 AM EST - 1 year ago

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Nov 13, 2023, 8:45 AM EST - 1 year ago

HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

Nov 3, 2023, 8:28 AM EDT - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

ARQT SINT

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

Sep 14, 2023, 4:15 PM EDT - 2 years ago

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

Sep 12, 2023, 4:15 PM EDT - 2 years ago

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

Sep 11, 2023, 4:15 PM EDT - 2 years ago

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India

Sep 7, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

Aug 31, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

HeartSciences' MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

Aug 24, 2023, 9:00 AM EDT - 2 years ago

HeartSciences' MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

Aug 17, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark

Jul 27, 2023, 9:00 AM EDT - 2 years ago

MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark

HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

Jul 19, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine

May 17, 2023, 8:00 AM EDT - 2 years ago

HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine

HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

May 9, 2023, 8:15 AM EDT - 2 years ago

HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

HeartSciences to Participate at the Inaugural EF Hutton Global Conference

May 8, 2023, 8:15 AM EDT - 2 years ago

HeartSciences to Participate at the Inaugural EF Hutton Global Conference

HeartSciences to Participate in The Benchmark Company's Virtual Individual Investor Healthcare Conference

May 2, 2023, 8:15 AM EDT - 2 years ago

HeartSciences to Participate in The Benchmark Company's Virtual Individual Investor Healthcare Conference

HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023

Apr 17, 2023, 8:15 AM EDT - 2 years ago

HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023

DrTampa
DrTampa Jul. 31 at 5:08 AM
$HSCS glad to see the offering is filling! We are 1/3 of the way done on the capital raise to see us through FDA submission approval and into commercialization!
0 · Reply
Moneyybaggs
Moneyybaggs Jul. 31 at 12:19 AM
$HSCS First of all, HSCS is raising $15 million and each unit is being issued at $3.50 per share with a $5 strike warrant that expires in three years. I spoke with the firm running the books and the raise is going very well.
0 · Reply
JerrieGauze
JerrieGauze Jul. 30 at 10:46 PM
$HSCS of July 29, 2025, the Company has received a total of $4.3 million of gross proceeds, resulting in the issuance of 1,241,188 Units, as a result of several closings of the Offering. they offered 15 million units. they need total 25 mil in shareholder value by sept 15 i know of one not personally( unless lying) is sweating this one. gl
0 · Reply
JerrieGauze
JerrieGauze Jul. 30 at 3:50 PM
$HSCS Science has left the building tongue blade ,ambu bag, and start heart compressions..more orders to come
0 · Reply
upmarketguy
upmarketguy Jul. 28 at 5:17 PM
$HSCS Out of this IDK why I got in it. Such light volume. Glad I didn't have much of it.
1 · Reply
DrTampa
DrTampa Jul. 28 at 4:33 AM
$HSCS I'm thinking this week could be very interesting...it didn't drop on earnings, and in fact had a little rally. Someone else sees the potential us long time holders see!
0 · Reply
d_risk
d_risk Jul. 25 at 4:59 PM
$HSCS - Heart Test Laboratories, Inc. - 10K - Updated Risk Factors HSCS’s 2025 10-K reveals expanded clinical trial and FDA compliance risks, heightened IP litigation and patent uncertainties, new dependency on Mount Sinai licenses, increased regulatory scrutiny on off-label use and inducements, added public company compliance burdens, potential stock dilution from preferred shares, and FINRA trading restrictions. #ClinicalTrials #StockDilution #RegulatoryScrutiny #IPLitigation #FDACompliance 🟢 Added 🟠 Removed https://d-risk.ai/HSCS/10-K/2025-07-24
1 · Reply
DrTampa
DrTampa Jul. 25 at 6:47 AM
$HSCS btw with the cash burn from the last quarter that they won't report for quite some time, I estimate another $1.5 million so shareholder equity is at about $2.3 million currently. keep in mind these are just estimates based on past expenses, and it's certainly not financial advice. But I think with the open offering taking place, we should definitely hit 3.5 million in equity by the end of the next quarter. We may not even need the NASDAQ extension which could grant us another 6 months for compliance if needed.
0 · Reply
14745Barclay
14745Barclay Jul. 24 at 10:35 PM
$HSCS Simpson, Hilz and Watson keep on giving themselves raises and bonuses and all the while dragging their feet with FDA submission of Myovista waveECG device. More excuses now with the some stupid update from ECG society guideline. Us long time shareholders have been suffering so much and these incompetent managers are milking us dry.
2 · Reply
DrTampa
DrTampa Jul. 24 at 8:19 PM
$HSCS 10-K just dropped! Reading it now :P
0 · Reply
14745Barclay
14745Barclay Jul. 24 at 7:43 PM
$HSCS Drop the god-$$MN news Simpson, what the F????
1 · Reply
DrTampa
DrTampa Jul. 24 at 5:29 AM
$HSCS I estimate we will have $3,800,000 in equity for this filing that should come out anytime soon. $1,790,000 equity at Q3 -$1,500,000 my estimate of cash burn for Q4 +$2,700,000 raised thru offering +$800,000 in debt swapped for shares -------------------- $3,790,000 my estimate of equity for share holders in next filing. This is bar napkin math, not actual numbers and certainly not financial advice.
0 · Reply
DrTampa
DrTampa Jul. 22 at 4:01 AM
$HSCS I think we saw the 8K drop today with updated share count and offering funding in preparation for 10Q this week🥳🥳
0 · Reply
DrTampa
DrTampa Jul. 21 at 4:39 PM
$HSCS based on past years, Q4 earnings and annual report should be out this week 🍻🥳
0 · Reply
snapbuy
snapbuy Jul. 19 at 10:13 PM
$HSCS
0 · Reply
snapbuy
snapbuy Jul. 19 at 10:05 PM
$HSCS It sound like is a very useful information and can really help the doctors quickly. Sound like a good value stock at this price
1 · Reply
5StaRScalper
5StaRScalper Jul. 19 at 10:46 AM
$HSCS well i have a buy order for 400 shares and 8k warrants. Around 2000 bucks which is about 1.8% of my portfolio. Seems like a safe bet. Definitely will not bet the farm but if this works out, it may be able to buy a farm. This is a trade you dont look at until you notice your portfolio is rising fast. On a side note: it looks like they dilute their shareholders alot so hopefully im coming in right at the breakthrough and havent been duped by wallstreet once again! Good luck fellow investors and traders!
1 · Reply
Moneyybaggs
Moneyybaggs Jul. 17 at 11:05 PM
$HSCS Talked with the firm handling the capital raise. You’re buying 1 share of convertible preferred at $3.50 per share which immediately converts to a common share and can then be placed in your brokerage account. Plus you get a warrant with a strike price of $5 and a 3-year expiration. This investment is a no-brainer!!!! SHOW ME THE MONEY!!! ECSTATICLY
1 · Reply
Tjcmd
Tjcmd Jul. 16 at 4:43 PM
$HSCS anyone else get this email?
2 · Reply
Moneyybaggs
Moneyybaggs Jul. 16 at 12:40 PM
$HSCS Because of the minuscule # of o/s shares HSCS could explode on any substantive PR and still be dramatically undervalued. It’s time for management to deliver!!! SUBSTANTIALLY
1 · Reply
DrTampa
DrTampa Jul. 16 at 3:09 AM
$HSCS new account, who dis?
1 · Reply
Moneyybaggs
Moneyybaggs Jul. 16 at 1:39 AM
$HSCS Gotta believe FDA submission is VERY CLOSE!!!
1 · Reply